AVEIR™ DR Dual Chamber Leadless Pacemaker System vs. Traditional Transvenous Pacemakers and Age‑Related Results in Leadless Patients: New Evidence Highlights Safety, Performance, and Patient Outcomes
Abbott Cardiac Rhythm Management | February 2, 2026
Dual chamber leadless pacemakers (LPs) have entered a transformative era — one defined not only by technological advancement, but by robust, real-world clinical outcomes. As more clinicians reevaluate conventional pacing strategies, the central question has become increasingly important: how do dual chamber leadless pacemakers truly compare to traditional transvenous pacemakers in real-world patient populations?
New evidence presented at APHRS 2025 provides a clear understanding of this comparison, offering a real-world insight into the safety and pacing performance of the AVEIR™ DR Dual Chamber LP System compared to traditional transvenous pacing.
Fewer Complications, Fewer Reinterventions, and Comparable Mortality
In the large, real-world Coverage with Evidence Development (CED) analysis evaluating 759 AVEIR DR Dual Chamber LP System patients versus 77,422 dual chamber transvenous patients, AVEIR DR Dual Chamber LP System demonstrated:
41% lower hazard of overall chronic complications at
6 months
52% lower hazard of device-related complications at
6 months
51% lower hazard of overall device reinterventions at 6 months
Comparable all-cause mortality at 30 days and
6 months
Exceptional Performance Even in Younger, Active Patients
12-month data from the IDE study evaluating the performance of AVEIR DR Dual Chamber LP System in patients <65 years vs ≥65 years demonstrated that AVEIR DR LP System performs exceptionally well even in younger, more active patients, including:
Greater than 99% implant success
100% atrioventricular (AV) synchrony at 3 months (Greater than 99% implant success in pts <65 yrs)
Significantly higher complication-free rates (91% vs 83%) compared to
older group
Significantly higher composite atrial pacing/sensing thresholds* (97% vs 90%) compared to older group
The above results are especially notable given the increased pacing demands, higher activity levels, and elevated peak heart rates often seen in younger patients.
Together, the evidence reinforces that dual chamber leadless pacing with AVEIR DR LP System delivers meaningful improvements in safety, performance, and patient outcomes. AVEIR DR LP System delivers fewer complications, fewer reinterventions, and dependable AV synchrony—even in younger, active patients who require durable long-term pacing.
*Acceptable atrial pacing/sensing thresholds defined as ≤3.0 V at 0.4 msec and P wave of ≥1.0 mV.
MAT-2600564 v2.0